Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase

Trial Profile

Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Imatinib (Primary) ; Dasatinib; Nilotinib; Radotinib
  • Indications Chronic myeloid leukaemia; Leukaemia; Myeloproliferative disorders
  • Focus Therapeutic Use
  • Acronyms IDEAL-E
  • Most Recent Events

    • 12 Jul 2016 Planned End Date changed from 1 Oct 2023 to 1 May 2023.
    • 12 Jul 2016 Planned primary completion date changed from 1 Oct 2023 to 1 May 2023.
    • 12 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top